



tixagevimab plus cilgavimab for preventing COVID-19

A Technology Appraisal collaboration with NICE

14 June 2023

The Scottish Medicines Consortium (SMC) collaborated with the National Institute for Health and Care Excellence (NICE) on *Technology Appraisal (TA) 900: tixagevimab plus cilgavimab for preventing COVID-19*. Following review by SMC Executive, SMC advises NHS boards and Area Drug and Therapeutics Committees (ADTCs) on the use of the product, below, in NHSScotland. The advice is as follows:

ADVICE: following SMC collaboration with NICE on *TA900: tixagevimab plus cilgavimab for preventing COVID-19*

The product has been considered within its marketing authorisation for preventing coronavirus disease 2019 (COVID-19), and this recommendation is valid for NHSScotland.

The recommendation of *TA900*, based on the clinical and cost effectiveness is:

SMC ID	Medicines	Indication	SMC advice
SMC2580	tixagevimab and cilgavimab (Evusheld®) 150mg/150mg solution for injection AstraZeneca UK Limited	Pre-exposure prophylaxis of COVID-19 in adults who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and: <ul style="list-style-type: none"> • who are unlikely to mount an adequate immune response to COVID-19 vaccination or • for whom COVID-19 vaccination is not recommended. 	Not recommended for use within NHSScotland

Full details of the assessment and recommendation can be found at [Overview | Tixagevimab plus cilgavimab for preventing COVID-19 | Guidance | NICE](#).

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was jointly arrived at following collaboration with NICE on NICE TA900: tixagevimab plus cilgavimab for preventing COVID-19 (dated 14/06/2023). It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chair

Scottish Medicines Consortium